|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 827 |
FusionGeneSummary for ADCY2_SH3BGRL3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ADCY2_SH3BGRL3 | Fusion gene ID: 827 | Hgene | Tgene | Gene symbol | ADCY2 | SH3BGRL3 | Gene ID | 108 | 83442 |
| Gene name | adenylate cyclase 2 | SH3 domain binding glutamate rich protein like 3 | |
| Synonyms | AC2|HBAC2 | HEL-S-297|SH3BP-1|TIP-B1 | |
| Cytomap | 5p15.31 | 1p36.11 | |
| Type of gene | protein-coding | protein-coding | |
| Description | adenylate cyclase type 23',5'-cyclic AMP synthetaseATP pyrophosphate-lyase 2adenylate cyclase 2 (brain)adenylate cyclase IIadenylate cyclase type IIadenylyl cyclase 2type II adenylate cyclase | SH3 domain-binding glutamic acid-rich-like protein 3SH3 domain binding glutamic acid-rich protein like 3SH3 domain-binding protein 1SH3BGRL3-like proteinTNF inhibitory proteinepididymis secretory protein Li 297 | |
| Modification date | 20180522 | 20180519 | |
| UniProtAcc | Q08462 | Q9H299 | |
| Ensembl transtripts involved in fusion gene | ENST00000338316, ENST00000537121, ENST00000513693, | ENST00000270792, ENST00000319041, | |
| Fusion gene scores | * DoF score | 20 X 19 X 5=1900 | 4 X 4 X 2=32 |
| # samples | 21 | 4 | |
| ** MAII score | log2(21/1900*10)=-3.17753818555219 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/32*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: ADCY2 [Title/Abstract] AND SH3BGRL3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BQ896787 | ADCY2 | chr1 | 152009422 | + | SH3BGRL3 | chr1 | 26606586 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-5UTR | ENST00000338316 | ENST00000270792 | ADCY2 | chr1 | 152009422 | + | SH3BGRL3 | chr1 | 26606586 | + |
| intron-intron | ENST00000338316 | ENST00000319041 | ADCY2 | chr1 | 152009422 | + | SH3BGRL3 | chr1 | 26606586 | + |
| intron-5UTR | ENST00000537121 | ENST00000270792 | ADCY2 | chr1 | 152009422 | + | SH3BGRL3 | chr1 | 26606586 | + |
| intron-intron | ENST00000537121 | ENST00000319041 | ADCY2 | chr1 | 152009422 | + | SH3BGRL3 | chr1 | 26606586 | + |
| intron-5UTR | ENST00000513693 | ENST00000270792 | ADCY2 | chr1 | 152009422 | + | SH3BGRL3 | chr1 | 26606586 | + |
| intron-intron | ENST00000513693 | ENST00000319041 | ADCY2 | chr1 | 152009422 | + | SH3BGRL3 | chr1 | 26606586 | + |
Top |
FusionProtFeatures for ADCY2_SH3BGRL3 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ADCY2 | SH3BGRL3 |
| Catalyzes the formation of the signaling molecule cAMPin response to G-protein signaling (PubMed:15385642). Down-streamsignaling cascades mediate changes in gene expression patterns andlead to increased IL6 production. Functions in signaling cascadesdownstream of the muscarinic acetylcholine receptors (Bysimilarity). {ECO:0000250|UniProtKB:P26769,ECO:0000269|PubMed:15385642}. | Could act as a modulator of glutaredoxin biologicalactivity. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ADCY2_SH3BGRL3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ADCY2_SH3BGRL3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ADCY2_SH3BGRL3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | ADCY2 | Q08462 | DB09121 | Aurothioglucose | Adenylate cyclase type 2 | small molecule | approved|withdrawn |
Top |
RelatedDiseases for ADCY2_SH3BGRL3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ADCY2 | C0004096 | Asthma | 1 | CTD_human |
| Hgene | ADCY2 | C0005586 | Bipolar Disorder | 1 | PSYGENET |
| Tgene | SH3BGRL3 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|